About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Vaxcyte shares rose 25.6% in premarket trading after the company said its pneumococcal vaccine met late-stage clinical trial endpoints.

2026-10-05

Vaxcyte shares rose 25.6% in premarket trading after the company said its pneumococcal vaccine met late-stage clinical trial endpoints.

Other News
2026-10-05

U.S. Treasury yields rose, with the 10-year Treasury yield up 2.34 basis points to 5.3% and the 30-year Treasury yield up 2.64 basis points to 5.656%.

U.S. Treasury yields rose, with the 10-year Treasury yield up 2.34 basis points to 5.3% and the 30-year Treasury yield up 2.64 basis points to 5.656%.
2026-10-05

Greece says this year’s budget surplus will exceed prior estimates as it submitted a fiscal plan to parliament. The government forecasts GDP growth of 2.0% in 2026, accelerating to 2.3% in 2027. The plan projects a 2026 budget surplus of 0.6% of GDP,

Greece says this year’s budget surplus will exceed prior estimates as it submitted a fiscal plan to parliament. The government forecasts GDP growth of 2.0% in 2026, accelerating to 2.3% in 2027. The plan projects a 2026 budget surplus of 0.6% of GDP, up from an earlier 0.3% target, and a 2027 surplus of 0.3% — marking a third consecutive year of surplus. Greece is one of four European countries expected to post a surplus this year; improved public finances have pushed Greek borrowing costs below those of France and Italy. MOODY’S raised Greece’s outlook to positive in September and Scope Ratings upgraded the sovereign to within one notch of A. The surplus will allow early repayment of about €13.0 bln of debt, cutting the debt ratio to 136.7% of GDP this year and to 128.8% by 2027, which would leave Italy with the highest debt-to-GDP in Europe.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.